Business
Lucid Diagnostics Provides Business Update and First Quarter Financial Results
EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16th at 8:30 AM EST
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year\nConference call and webcast to be held tomorrow, May 16th at 8:30 AM EST\nNEW YORK, May 15, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( \"PAVmed\"), today provided a business update for the Company and presented financial results for the three months ended March 31, 2023.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast\nThe webcast will take place on Tuesday, May 16, 2023, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 877-870-4263 and international listeners should dial 412-317-0790. All listeners should provide the operator with the conference call name \"Lucid Diagnostics Business Update\" to join.\nBusiness Update Highlights\n\"Lucid had a strong start in the first quarter of 2023, with robust sequential growth in EsoGuard testing volume,\" said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. \"We attribute this progress to our relentless focus on EsoGuard commercial expansion, including the growing popularity and utilization of our satellite Lucid Test Center (sLTC) program, a broad expansion of #CheckYourFoodTube Precancer Detection Events (#CYFT) and growing awareness of EsoGuard as a much-needed widespread screening tool that is highly effective in detecting esophageal precancer in a sizeable at-risk patient population.\"\nHighlights from the first quarter and recent weeks:\nLucid's CLIA-certified clinical laboratory performed 1,841 commercial EsoGuard® Esophageal DNA Tests in the 1Q23, which represents a 57 percent increase sequentially from 4Q22 and a 245 percent annual increase from 1Q22.Satellite Lucid Test Center (sLTC) activity, whereby Lucid clinicians collect samples at physician offices or high-volume testing events, continues to increase rapidly, representing 51 percent of all samples collected in 1Q23, up from 31 percent in 4Q22.In January, Lucid launched its #CheckYourFoodTube Precancer Detection Event (#CYFT Event) program, bringing EsoGuard testing directly to at-risk pat...